MedTrace Logo

PET-MRI After Radiofrequency Ablation (RFA) or Microwave Ablation (MWA)

NCT01895673 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2016-12-15

No results posted yet for this study

Summary

The primary objective of this study is to evaluate the ability of PET-MRI and to detect a local site recurrence during the first year of follow-up after RFA or MWA of colorectal liver metastases (CRLM) as compared with contrast enhanced (ce) CT and PET-CT. Standard reference will be clear focal uptake in the rim of the lesion on PET-CT, possibly in combination with histology (when available) or clinical follow-up.

Secondary outcomes are the inter-observer variability, the ability to diagnose new intrahepatic lesions and in what way PET-MRI is able to influence future treatment compared to PET-CT and ceCT. The patients satisfaction concerning the PET-MRI will be examined with a questionnaire.

Conditions

  • Liver Neoplasms
  • Local Neoplasm Recurrence

Interventions

OTHER

Gadolinium

All patients will undergo PET-MRI additional to the PET-CT they routinely undergo. All patients will be administered Gadolinium for the PET-MRI scan. This is an extra intervention than they would normally undergo.

Sponsors & Collaborators

  • dr. M.P. van den Tol MD PhD

    lead OTHER

Principal Investigators

  • Petrousja van den Tol, MD PhD · VU University Medical Centre

  • Indra C Pieters, MD PhD · VU University Medical Centre

  • Emile FI Comans, MD PhD · VU University Medical Centre

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2016-06-30
Completion
2016-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01895673 on ClinicalTrials.gov